McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple Turns 50: From Garage Startup to AI Crossroads 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
DUBLIN, Ireland, Dec. 22, 2016 -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it plans to present at the 35th Annual J.P. Morgan Healthcare Conference. Timothy P. Walbert, chairman, president and chief executive officer, will present at 7:30 a.m. Pacific Time on January 10, 2017.
The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com. A replay of the webcast will be available following the event.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. Horizon Pharma markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Investors: Tina Ventura Senior Vice President, Investor Relations [email protected] U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications [email protected] Ireland Media: Ray Gordon Gordon MRM [email protected]
